TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
Cora Sternberg, MD, FACP, Weill Cornell Medicine
Advertisement
Articles by Cora Sternberg, MD, FACP, Weill Cornell Medicine
Advertisement
Latest Updated Articles
Rapid Readouts: TROPHY-U-01 Cohort 1 Final ResultsOctober 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
3
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5